Literature DB >> 30038649

Case report of a dose-volume histogram analysis of rib fracture after accelerated partial breast irradiation: interim analysis of a Japanese prospective multi-institutional feasibility study.

Ken Yoshida1, Yuki Otani2, Takayuki Nose3, Eisaku Yoden4, Shuuji Asahi5, Iwao Tsukiyama6, Takushi Dokiya7, Toshiaki Saeki8, Ichirou Fukuda9, Hiroshi Sekine10, Yu Kumazaki11, Takao Takahashi12, Tadayuki Kotsuma13, Norikazu Masuda14, Kazutaka Nakashima15, Taisei Matsumura16, Shino Nakagawa17, Seiji Tachiiri18, Yoshio Moriguchi19, Jun Itami20, Masahiko Oguchi21.   

Abstract

We initiated the first multi-institutional prospective study of accelerated partial breast irradiation for early breast cancer in Japan. Our early clinical results showed that the treatment methods were technically reproducible between institutions and showed excellent disease control at a median follow-up of 26 months in our previous report. At present, total 46 patients from six institutions underwent the treatment regimen from October 2009 to December 2011, and the median follow-up time was 60 months (range, 57-67 months). In 46 patients, we experienced one patient who had rib fracture as a late complication. The dose-volume histogram (DVH) result of this patient was analyzed. The D0.01cc, D0.1cc, and D1cc values of the patient were 913, 817, and 664 cGy per fraction, respectively. These values were the highest values in 46 patients. The average D0.01cc, D0.1cc, and D1cc values of the other 45 patients were 546, 500, and 419, respectively, cGy per fraction. From this result, DVH values showing high-dose irradiated volume (D0.01cc, D0.1cc, and D1cc) seem to be a good predictive factor of rib fracture for accelerated partial breast irradiation. However, further investigation is necessary because of the small number of patients investigated.

Entities:  

Keywords:  accelerated partial breast irradiation; breast cancer; dose-volume histogram; rib fracture

Year:  2018        PMID: 30038649      PMCID: PMC6052388          DOI: 10.5114/jcb.2018.76983

Source DB:  PubMed          Journal:  J Contemp Brachytherapy        ISSN: 2081-2841


Purpose

Breast-conserving surgery with postoperative radiation therapy is a standard of care for early breast cancer. The most common radiation therapy technique is whole-breast radiotherapy (WBRT), which has been proven to reduce the rate of local recurrence by one-third [1, 2]. However, completion of WBRT takes 5 to 6 weeks, which is sometimes a problem for working patients or with children as well as for elderly patients or for those who live far from a treatment facility. Recently, a hypofractionation schedule has been tried for WBRT to reduce the treatment time; however, treatment lasting for more than 3 weeks is still necessary [3, 4]. Accelerated partial breast irradiation (APBI) may present a solution to the issues associated with WBRT. This method requires a much shorter treatment time (e.g. one day [5] to several days) than WBRT. Recently, the results of a phase III clinical trial in Europe were published and demonstrated the non-inferiority of APBI when compared with whole-breast irradiation [6]. In Japan, APBI was introduced in 1998 and showed good preliminary results [7, 8]. The present study is the first multi-institutional prospective study of APBI in Japan. Early clinical results, including detailed treatment methods, have been published [9, 10, 11]. The results showed that the treatment methods were technically reproducible between institutions and showed excellent disease control at a median follow-up of 26 months [10]. However, we reported one patient who experienced rib fracture as a late complication [10]. This is a rare complication in patients who receive WBRT. In this report, we analyze the dose-volume histogram (DVH) of the rib to evaluate the threshold doses for rib fracture.

Case report

The treatment protocol was registered at the University Hospital Medical Information Network Clinical Trials Registry and was approved by participating institutional review boards. Patient eligibility criteria are summarized in Table 1. Although molecular subtype should be included or not is controversial [12], we did not include Her2 status. Forty-six patients from six institutions underwent treatment regimen from October 2009 to December 2011. The median follow-up time was 60 months (range, 57-67 months). Written informed consent was obtained from all patients.
Table 1

Patient eligibility criteria

Female invasive/noninvasive ductal/lobular cancer ≤ 3 cm
pN0
cM0
ER positive and/or PR positive
Surgical margin: cancer not exposed
Surgical margin marked with at least 4 clips
No pre-surgical treatment except for hormonal treatment
Age ≥ 35 years
Written informed consent
Performance status: 0 or 1
No collagen vascular diseases except rheumatoid arthritis
Patient eligibility criteria All patients underwent breast-conserving surgery, in which surgical clips were implanted in the resection margins. We confirmed the presence of negative surgical margins and negative metastatic lymph nodes before radiation. Applicators were generally implanted in two or more planes. Treatment plans were calculated by three-dimensional brachytherapy planning. In planning computed tomography (CT) images, 15 mm radius balloons were drawn around the surgical clips. The spaces between the balloons were interpolated clinically, and the reproduced volume was defined as the clinical target volume (CTV). To reduce the interobserver variations of CTV delineation [13], a dummy run was completed, and one physician (KY) participates in the treatment for a first patient of almost all institutes. The skin (5 mm thickness from the surface) and chest wall were excluded from the target volume. In numerous planning methods [14], we used the Paris dose calculation system with manual modifications. The prescribed doses were 36 Gy per six fractions in 3 days, with an interval of 6 hours between two fractions on the same day. This dose-fractionation schedule is biologically similar to schedules of Hungary group [15] and Azerbaijan group [16]. High-dose-rate brachytherapy with an Ir-192 source was used. To control the quality of brachytherapy, dose constraints were set as follows. The reference volume (Vref), which was the irradiated volume receiving ≥ 100% of the prescribed dose was principally limited to less than 150 cm3. The dose non-uniformity ratio (DNR), which was defined as V1.5ref/Vref was less than 0.35. V1.5ref is the irradiated volume receiving ≥ 150% of the prescribed dose. The clip dose had to be more than or equal to 6 Gy per fraction. The rib was drawn into the planning CT as an organ at risk, and the minimum dose received by the maximally irradiated 0.01, 0.1, and 1 cc volumes (D0.01cc, D0.1cc, and D1cc) were calculated. Systemic therapy was performed according to each institute’s treatment policy. Chemotherapy was not allowed during the protocol treatment period and for 2 weeks thereafter. All clinical data were prospectively collected every 2 weeks for 1 month, every 3 months until 24 months after treatment, and every 6 months thereafter up to 60 months. These items were scored by the physician according to the Common Terminology Criteria for Adverse Events ver. 3.0 (CTCAE v3). The case patient was a 43-year-old woman with an adenocarcinoma on the left breast that was staged pT2N0M0 using the 2002 UICC classification. The tumor was positive for estrogen and progesterone receptors. Fifteen flexible applicator tubes were implanted (Figure 1A). She complained of chest wall pain 9 months after treatment, and the CT image showed rib fracture at 11 months after treatment (Figure 1B). The fracture was judged as Grade 2 of CTCAE v3, and it healed 18 months after treatment.
Fig. 1

A) Dose distribution curve of a patient who had a rib fracture as a late complication. The arrow shows the rib that was fractured. White dotted line: 100% prescribed isodose line (36 Gy per six fractions). White solid line: 150% prescribed isodose line (54 Gy per six fractions). Red line: clinical target volume. B) Computed tomography image of the patient shown in (Figure 1A) 11 months after treatment. The arrow shows the rib that was fractured

A) Dose distribution curve of a patient who had a rib fracture as a late complication. The arrow shows the rib that was fractured. White dotted line: 100% prescribed isodose line (36 Gy per six fractions). White solid line: 150% prescribed isodose line (54 Gy per six fractions). Red line: clinical target volume. B) Computed tomography image of the patient shown in (Figure 1A) 11 months after treatment. The arrow shows the rib that was fractured The DVH result of this patient is that Vref and V1.5ref were 112 cc and 34.7 cc, respectively, and DNR was 0.31. CTV volume was 40 cc. Eight clips were implanted, and the clip doses were 713 to 1,083 cGy per fraction. D90 (CTV) and D100 (CTV) were 696 and 614 cGy per fraction, respectively. The D0.01cc, D0.1cc, and D1cc values of the rib were 913, 817, and 664 cGy per fraction, respectively. The D0.01cc, D0.1cc, and D1cc values for the total six fractions were 54.8, 49.0, and 39.8 Gy, respectively. The biologically equivalent doses that were calculated as equivalent 2 Gy fractions (EQD2) were 132.9, 109.5, and 76.8 Gy (α/β = 3). The average D0.01cc, D0.1cc, and D1cc values of the other 45 patients were 546, 500, and 419 cGy per fraction, respectively. We present these DVH values of the rib for all 46 patients (Figure 2A-C). DVH values of this patient were higher than those of other 45 patients.
Figure 2

A) D0.01cc values of the rib for all 46 patients. The patient who had a rib fracture was number 37 (red line). The D0.01cc value of the rib was 913 cGy per fraction. B) D0.1cc values of the rib for all 46 patients. The patient who had a rib fracture was number 37 (red line). The D0.1cc value of the rib was 817 cGy per fraction. C) D1cc values of the rib for all 46 patients. The patient who had a rib fracture was number 37 (red line). The D1cc value of the rib was 664 cGy per fraction

A) D0.01cc values of the rib for all 46 patients. The patient who had a rib fracture was number 37 (red line). The D0.01cc value of the rib was 913 cGy per fraction. B) D0.1cc values of the rib for all 46 patients. The patient who had a rib fracture was number 37 (red line). The D0.1cc value of the rib was 817 cGy per fraction. C) D1cc values of the rib for all 46 patients. The patient who had a rib fracture was number 37 (red line). The D1cc value of the rib was 664 cGy per fraction

Discussion

Rib fracture after conventional radiotherapy generally has a low incidence. However, hypofraction radiotherapy schedule seems to be associated with a higher rate of rib fracture. Nambu et al. reported the results of stereotactic body radiotherapy (SBRT) for lung cancer [17]. They administered 48 to 70 Gy per 4 to 10 fractions. Rib fracture was observed in 14/41 (34%). Proton therapy was also associated with a higher rate of rib fracture. Kanemoto et al. reported that 11 of 67 patients (16.4%) treated with doses of 66 cobalt-gray equivalents per 10 fractions for hepatocellular carcinoma had rib fractures [18]. APBI may show similar results. Galland-Girodet et al. reported that 4 of 98 patients (4%) treated with three-dimensional conformal APBI using photons with or without electron and proton therapy had rib fractures [19]. Hershko et al. reported that 4 of 21 patients (19%) undergoing APBI with intraoperative electron therapy who did not use lead shielding had rib fractures [20]. Yoshida et al. reported that 2 of 45 Japanese patients (4%) had minor rib fractures, which were healed at the time of the latest follow-up [8]. Smith et al. analyzed the results from 92,735 patients from the SEER-Medicare database, and reported that the rate of rib fracture was significantly higher with brachytherapy (4.5%) than with whole-breast radiotherapy (3.6%) [21]. They did not evaluate the difference between single-channel brachytherapy and multichannel brachytherapy. Huo et al. analyzed the results from 64,112 patients using MarketScan healthcare claims and the Encounters database, and reported that the rate of rib fracture was significantly higher with brachytherapy (1.6%) than with whole-breast radiotherapy (1.3%) [22]. However, the 2,269 patients who received multichannel brachytherapy had a lower rate of rib fracture (1.3%) than the 2,203 patients who received single-channel brachytherapy (1.8%). These results suggest that the outcome of multicatheter interstitial brachytherapy is better than that of single-channel brachytherapy with respect to rib fracture. To prevent rib fracture, dose-volume analysis may be useful. Many studies have performed dose-volume analyses of the relation between rib fracture and SBRT and proton therapy [17, 18, 23, 24, 25, 26]. Asai et al. reported that the best predictor of rib fracture from SBRT was the maximum dose (Dmax) of the rib [24]. Rib fracture occurred in 45.8% of cases when Dmax was greater than or equal to 42.4 Gy per four fractions, and in only 1.4% of cases when Dmax was less than 42.4 Gy per four fractions. The EQD2 for 42.4 Gy per four fractions was 115.3 Gy. The present study showed that the EQD2 of the fractured rib was 132.9 and 109.5 Gy for D0.01cc and D0.1cc, respectively. These results are similar to Asai’s outcomes. There are few data on DVH of patients undergoing APBI, and this case is now under investigation. Brashears et al. reported that 3 of 105 patients (3%) treated by MammoSite applicator had five ribs fractures. They analyzed the DVH results for these five ribs and found that the maximum doses to 0.1 and 1 cc were 35.4-58.3 and 28.2-45 Gy per 10 fractions, respectively [27]. The present study showed that the D0.1cc and D1cc values of the patient who had a rib fracture were 49.0 and 39.8 Gy per six fractions, respectively. These are also comparable to Brashears’s results. The relationship between irradiated volume and rib fracture was unknown. However, there is a report that Vref, V1.5ref, and V2ref were significant risk factors of fat necrosis [28]. In this study, V1.5ref was 34.7 cc although CTV volume was 40 cc. Such high-dose volume may influence rib fracture, although further research is necessary. From the above discussion, DVH values showing high-dose irradiated volumes (D0.01cc, D0.1cc, and D1cc) seem to be good predictive factors of rib fracture with APBI. However, further investigation is necessary because of the small number of investigated patients.
  28 in total

1.  Preliminary result of accelerated partial breast irradiation after breast-conserving surgery.

Authors:  Ken Yoshida; Takayuki Nose; Norikazu Masuda; Hideya Yamazaki; Tadayuki Kotsuma; Mineo Yoshida; Jun Yamamura; Hiroko Masuda; Eisei Shin; Hiroyuki Nakaba; Yoshifumi Komoike; Yukiko Tokuda; Masashi Takeda; Keiko Kuriyama
Journal:  Breast Cancer       Date:  2008-09-20       Impact factor: 4.239

2.  Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy: risk factors and dose-volume relationship.

Authors:  Kaori Asai; Yoshiyuki Shioyama; Katsumasa Nakamura; Tomonari Sasaki; Saiji Ohga; Takeshi Nonoshita; Tadamasa Yoshitake; Kayoko Ohnishi; Kotaro Terashima; Keiji Matsumoto; Hideki Hirata; Hiroshi Honda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-23       Impact factor: 7.038

3.  A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy: clinical results with a median follow-up of 26 months.

Authors:  Takayuki Nose; Yuki Otani; Shuuji Asahi; Iwao Tsukiyama; Takushi Dokiya; Toshiaki Saeki; Ichirou Fukuda; Hiroshi Sekine; Naoto Shikama; Yu Kumazaki; Takao Takahashi; Ken Yoshida; Tadayuki Kotsuma; Norikazu Masuda; Eisaku Yoden; Kazutaka Nakashima; Taisei Matsumura; Shino Nakagawa; Seiji Tachiiri; Yoshio Moriguchi; Jun Itami; Masahiko Oguchi
Journal:  Breast Cancer       Date:  2015-10-14       Impact factor: 4.239

4.  Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer.

Authors:  Grace L Smith; Ying Xu; Thomas A Buchholz; Sharon H Giordano; Jing Jiang; Ya-Chen Tina Shih; Benjamin D Smith
Journal:  JAMA       Date:  2012-05-02       Impact factor: 56.272

5.  Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer.

Authors:  Timothy Whelan; Robert MacKenzie; Jim Julian; Mark Levine; Wendy Shelley; Laval Grimard; Barbara Lada; Himu Lukka; Francisco Perera; Anthony Fyles; Ethan Laukkanen; Sunil Gulavita; Veronique Benk; Barbara Szechtman
Journal:  J Natl Cancer Inst       Date:  2002-08-07       Impact factor: 13.506

6.  Late chest wall toxicity after MammoSite breast brachytherapy.

Authors:  James H Brashears; Anthony E Dragun; Joseph M Jenrette
Journal:  Brachytherapy       Date:  2008-10-26       Impact factor: 2.362

7.  Contemporary Toxicity Profile of Breast Brachytherapy Versus External Beam Radiation After Lumpectomy for Breast Cancer.

Authors:  Jinhai Huo; Sharon H Giordano; Benjamin D Smith; Simona F Shaitelman; Grace L Smith
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-12-17       Impact factor: 7.038

8.  Breast-conserving surgery and intraoperative electron radiotherapy in early breast cancer: experience at the Rambam Health Care Campus.

Authors:  Dan Hershko; Roxolyana Abdah-Bortnyak; Alexander Nevelsky; Eliahu Gez; Georgeta Fried; Abraham Kuten
Journal:  Isr Med Assoc J       Date:  2012-09       Impact factor: 0.892

9.  Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial.

Authors:  Csaba Polgár; Zoltán Sulyok; János Fodor; Zsolt Orosz; Tibor Major; Zoltán Takácsi-Nagy; László C Mangel; András Somogyi; Miklós Kásler; György Németh
Journal:  J Surg Oncol       Date:  2002-07       Impact factor: 3.454

10.  High-dose-rate interstitial brachytherapy for accelerated partial breast irradiation - trial results of Azerbaijan National Center of Oncology.

Authors:  Jamil A Aliyev; Isa H Isayev; Kamal S Akbarov; Samir S Qurbanov; Ruslan R Huseynov; Nigar S Aliyeva
Journal:  J Contemp Brachytherapy       Date:  2017-04-13
View more
  2 in total

1.  Catheter-based delineation of lumpectomy cavity for accurate target definition in partial-breast irradiation with multicatheter interstitial brachytherapy.

Authors:  Kazuhiko Sato; Takahiro Shimo; Hiromi Fuchikami; Naoko Takeda; Masahiro Kato; Tomohiko Okawa
Journal:  J Contemp Brachytherapy       Date:  2019-04-29

2.  Experience in multicatheter interstitial high-dose-rate breast brachytherapy: dose-volume histogram analysis of the first results.

Authors:  Alena Demianovich; Dmitriy Sanin; Valeriya Martynova; Natalia Borysheva; Aleksandr Obuhov; Gamzat Aminov; Igor Gulidov; Yuriy Mardyntsky; Marina Kiseleva; Sergey Ivanov; Andrey Kaprin
Journal:  J Contemp Brachytherapy       Date:  2019-08-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.